Literature DB >> 24149370

Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGΒ4-PDCD4) as predictor of metastatic tumor potential.

Angelo Ferraro1, Christos K Kontos1, Themis Boni1, Ioannis Bantounas1, Dimitra Siakouli1, Vivian Kosmidou1, Margarita Vlassi1, Yannis Spyridakis2, Iraklis Tsipras2, George Zografos2, Alexander Pintzas1.   

Abstract

Previous studies have uncovered several transcription factors that determine biological alterations in tumor cells to execute the invasion-metastasis cascade, including the epithelial-mesenchymal transition (EMT). We sought to investigate the role of miR-21 in colorectal cancer regulation. For this purpose, miR-21 expression was quantified in a panel of colorectal cancer cell lines and clinical specimens. High expression was found in cell lines with EMT properties and in the vast majority of human tumor specimens. We demonstrate in a cell-specific manner the occupancy of MIR-21 gene promoter by AP-1 and ETS1 transcription factors and, for the first time, the pattern of histone posttranslational modifications necessary for miR-21 overexpression. We also show that Integrin-β4 (ITGβ4), exclusively expressed in polarized epithelial cells, is a novel miR-21 target gene and plays a role in the regulation of EMT, since it is remarkably de-repressed after transient miR-21 silencing and downregulated after miR-21 overexpression. miR-21-dependent change of ITGβ4 expression significantly affects cell migration properties of colon cancer cells. Finally, in a subgroup of tumor specimens, ROC curve analysis performed on quantitative PCR data sets for miR-21, ITGβ4, and PDCD4 shows that the combination of high miR-21 with low ITGβ4 and PDCD4 expression is able to predict presence of metastasis. In conclusion, miR-21 is a key player in oncogenic EMT, its overexpression is controlled by the cooperation of genetic and epigenetic alterations, and its levels, along with ITGβ4 and PDCD4 expression, could be exploited as a prognostic tool for CRC metastasis.

Entities:  

Keywords:  ITGβ4; RAS; epithelial-mesenchymal transition (EMT); histone modifications; metastasis markers; miR-21

Mesh:

Substances:

Year:  2013        PMID: 24149370      PMCID: PMC3928175          DOI: 10.4161/epi.26842

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  66 in total

1.  PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis.

Authors:  Matteo Fassan; Marco Pizzi; Luciano Giacomelli; Claudia Mescoli; Kathrin Ludwig; Salvatore Pucciarelli; Massimo Rugge
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

Review 2.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

3.  Integrin α6β4 in colorectal cancer.

Authors:  Jean-François Beaulieu
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

4.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

Review 5.  Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.

Authors:  Ping Chi; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

6.  Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer.

Authors:  Hajime Shibuya; Hisae Iinuma; Ryu Shimada; Atsushi Horiuchi; Toshiaki Watanabe
Journal:  Oncology       Date:  2011-03-17       Impact factor: 2.935

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

8.  Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation.

Authors:  Xiaoqing Li; Jun Liu; Rui Zhou; Shi Huang; Shiang Huang; Xian-Ming Chen
Journal:  Br J Haematol       Date:  2009-10-05       Impact factor: 6.998

9.  Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells.

Authors:  Ignacio Mazón Peláez; Margarita Kalogeropoulou; Angelo Ferraro; Angeliki Voulgari; Tibor Pankotai; Imre Boros; Alexander Pintzas
Journal:  Int J Biochem Cell Biol       Date:  2010-01-28       Impact factor: 5.085

10.  FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders.

Authors:  Gennaro Chiappetta; Angelo Ferraro; Gerardo Botti; Mario Monaco; Rosa Pasquinelli; Emilia Vuttariello; Liliane Arnaldi; Maurizio Di Bonito; Giuseppe D'Aiuto; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  BMC Cancer       Date:  2007-01-25       Impact factor: 4.430

View more
  46 in total

1.  Programmed cell death factor 4 enhances the chemosensitivity of colorectal cancer cells to Taxol.

Authors:  Daqing Wang; Qianqian Hou; Lingjun Zhao; Jun Gao; Yang Xiao; Anhua Wang
Journal:  Oncol Lett       Date:  2019-05-27       Impact factor: 2.967

2.  MicroRNA Expression and Correlation with mRNA Levels of Colorectal Cancer-Related Genes.

Authors:  Farahnaz Moghadamnia; Pegah Ghoraeian; Sara Minaeian; Atefeh Talebi; Farnaz Farsi; Abolfazl Akbari
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis.

Authors:  Panagiotis G Adamopoulos; Margarita C Theodoropoulou; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

4.  MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis.

Authors:  Katherine A Kelley; Nicole Wieghard; Yuki Chin; Amiee Potter; Motomi Mori; Melissa H Wong; Koei Chin; V Liana Tsikitis
Journal:  Dis Colon Rectum       Date:  2018-11       Impact factor: 4.585

Review 5.  Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.

Authors:  Marios A Diamantopoulos; Panagiotis Tsiakanikas; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

6.  A miRNA signature for an environmental heterocyclic amine defined by a multi-organ carcinogenicity bioassay in the rat.

Authors:  Ying-Shiuan Chen; Rong Wang; Wan-Mohaiza Dashwood; Christiane V Löhr; David E Williams; Emily Ho; Susanne Mertens-Talcott; Roderick H Dashwood
Journal:  Arch Toxicol       Date:  2017-03-13       Impact factor: 5.153

7.  Berberine regulates the microRNA-21-ITGΒ4-PDCD4 axis and inhibits colon cancer viability.

Authors:  Yanfeng Lü; Bingbing Han; Hualong Yu; Zhenghua Cui; Zhiwen Li; Jianxin Wang
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

Review 8.  Overview upon miR-21 in lung cancer: focus on NSCLC.

Authors:  Cecilia Bica-Pop; Roxana Cojocneanu-Petric; Lorand Magdo; Lajos Raduly; Diana Gulei; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

9.  microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion.

Authors:  Amit Bera; Falguni Das; Nandini Ghosh-Choudhury; Balakuntalam S Kasinath; Hanna E Abboud; Goutam Ghosh Choudhury
Journal:  Exp Cell Res       Date:  2014-07-09       Impact factor: 3.905

10.  Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.

Authors:  Lei Tian; Weiyu Shan; Yufei Zhang; Yufei Zhnag; Xuejun Lv; Xuehua Li; Caiyun Wei
Journal:  Pathol Oncol Res       Date:  2015-10-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.